01 / ATLAS

What it is

DSIP stands for “delta sleep-inducing peptide” and is also known as emideltide. It has been investigated in sleep research. The name is not a guarantee that it induces sleep. [1]

02 / ATLAS

How it works

Research has examined effects on sleep structure and quality. The cited study does not provide a sufficient clinical explanation to predict who would benefit from administration. [1]

03 / ATLAS

What research shows

A double-blind study in people with chronic insomnia reported some differences in sleep efficiency and time to fall asleep. The authors considered the effects weak and potentially influenced by chance changes in the placebo group. [1]

04 / ATLAS

Study data

Bes et al., 1992: assessment using polysomnography and subjective ratings. The study is old, and the findings do not provide a sufficient basis for current clinical recommendations or self-medication doses. [1]

05 / ATLAS

Safety and observed adverse reactions

The FDA describes insufficient safety information for the proposed route and potential immunogenicity and impurity concerns. [2]

06 / ATLAS

Research status

The selected clinical evidence is limited. DSIP is not presented here as a validated insomnia treatment; persistent sleep disturbances require evaluation of their cause.

07 / REFERENCES

Studies and sources

  1. Bes et al. · DSIP in chronic insomnia (1992) ↗Original research · double-blind study
  2. FDA · Emideltide / DSIP ↗Official assessment · United States
Back to the atlasFurther information / Contact